20 resultater (0,25311 sekunder)

Mærke

Butik

Pris (EUR)

Nulstil filter

Produkter
Fra
Butikker

The Safe Use Initiative and Health Literacy - Institute Of Medicine - Bog - National Academies Press - Plusbog.dk

Communicating Clearly About Medicines - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Communicating Clearly About Medicines - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Research conducted over the past two decades has shown that poor patient understanding of medication instructions is an important contributor to the more than 1 million medication errors and adverse drug events that lead to office and emergency room visits, hospitalizations, and even death. Patients who have limited literacy skills, who have multiple comorbidities, and who are elderly face the greatest risk, and limited literacy skills are significantly associated with inadequate understanding and use of prescription instructions and precautions. The Agency for Healthcare Research and Quality notes that only 12 percent of U.S. adults have proficient health literacy that allows them to interpret a prescription label correctly. Given the importance of health literacy to the proper use of medications, and the apparent lack of progress in improving medication adherence, the Roundtable on Health Literacy formed an ad hoc committee to plan and conduct a 1-day public workshop that featured invited presentations and discussion of the role and challenges regarding clarity of communication on medication. Participants focused on using health literacy principles to address clarity of materials, decision aids, and other supportive tools and technologies regarding risks, benefits, alternatives, and health plan coverage. This publication summarizes the presentations and discussions from the workshop. Table of ContentsFront Matter1 Introduction and Workshop Overview2 Patient and Caregiver Perspectives3 Approaches to Health-Literate Medication Instructions4 Translating Research into Practice: Case Studies5 Exploring the Future of Health-Literate Design6 Reflections on the DayReferencesAppendix A: Workshop AgendaAppendix B: Biographical Sketches of Workshop Speakers, Moderators, and Reactors

DKK 344.00
1

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease - Board On Health Sciences Policy - Bog - National Academies Press - Plusbog.dk

An Approach to Evaluate the Effects of Concomitant Prescribing of Opioids and Benzodiazepines on Veteran Deaths and Suicides - Health And Medicine

An Approach to Evaluate the Effects of Concomitant Prescribing of Opioids and Benzodiazepines on Veteran Deaths and Suicides - Health And Medicine

Opioid prescriptions for acute and chronic pain increased dramatically from the late 1990s into the current decade in both the civilian and the Department of Veterans Affairs and Department of Defense treatment environments. Similarly, prescriptions for benzodiazepines also increased significantly for anxiety and insomnia. Combinations of opioid and benzodiazepines have proven fatal when taken concurrently, with research demonstrating this phenomenon for nearly 40 years. This issue is exacerbated within the veteran population because of higher rates of pain, anxiety and other related health issues due to military life. An evaluation of the relationship between opioid and benzodiazepine medication practices at the VA is necessary to improve treatment for mental health and combat-related trauma for veterans. An Approach to Evaluate the Effects of Concomitant Prescribing of Opioids and Benzodiazepines on Veteran Deaths and Suicides investigates the effects of opioid initiation and tapering strategies in the presence of benzodiazepines in veterans. This report explores neurobiology and the principles of addiction and tolerance, in addition to the current use of opioids and benzodiazepines for treating pain and anxiety in both the veteran and general population. It also provides a protocol to evaluate the relationship between opioid and benzodiazepine medication practices. This framework is a critical foundation for further research to improve concomitant opioid and benzodiazepine medication practices for veterans and the general population. Table of ContentsFront MatterSummary1 Introduction2 Specifying the Target Trial3 Observational Emulationof the Target Trials and Practical Considerations

DKK 318.00
1

Medications for Opioid Use Disorder Save Lives - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Medications for Opioid Use Disorder Save Lives - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already exist—like evidence-based medications—are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed. Table of ContentsFront MatterSummary1 Introduction2 The Effectiveness of Medication-Based Treatment for Opioid Use Disorder3 Treatment with Medications for Opioid Use Disorder in Different Populations4 Medications for Opioid Use Disorder in Various Treatment Settings5 Barriers to Broader Use of Medications to Treat Opioid Use DisorderAppendix A: Study Approach and MethodsAppendix B: Public Workshop AgendaAppendix C: Biographical Sketches of Committee Members

DKK 344.00
1

Compounded Topical Pain Creams - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Compounded Topical Pain Creams - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Pain is both a symptom and a disease. It manifests in multiple forms and its treatment is complex. Physical, social, economic, and emotional consequences of pain can impair an individual's overall health, well-being, productivity, and relationships in myriad ways. The impact of pain at a population level is vast and, while estimates differ, the Centers for Disease Control and Prevention reported that 50 million U.S. adults are living in pain. In terms of pain's global impact, estimates suggest the problem affects approximately 1 in 5 adults across the world, with nearly 1 in 10 adults newly diagnosed with chronic pain each year. In recent years, the issues surrounding the complexity of pain management have contributed to increased demand for alternative strategies for treating pain. One such strategy is to expand use of topical pain medications—medications applied to intact skin. This nonoral route of administration for pain medication has the potential benefit, in theory, of local activity and fewer systemic side effects. Compounding is an age-old pharmaceutical practice of combining, mixing, or adjusting ingredients to create a tailored medication to meet the needs of a patient. The aim of compounding, historically, has been to provide patients with access to therapeutic alternatives that are safe and effective, especially for people with clinical needs that cannot otherwise be met by commercially available FDA-approved drugs. Compounded Topical Pain Creams explores issues regarding the safety and effectiveness of the ingredients in these pain creams. This report analyzes the available scientific data relating to the ingredients used in compounded topical pain creams and offers recommendations regarding the treatment of patients. Table of ContentsFront MatterSummary1 Introduction2 Role of Topical Pain Creams in Pain Management3 Fundamentals, Use, and Common Ingredients in Compounded Topical Pain Creams4 Gaps in Regulation, Oversight, and Surveillance5 Science of Compounded Topical Pain Creams6 A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams7 Additional Concerns Related to the Use of Compounded Topical Pain Creams8 Recommendations Regarding the Treatment of Patients with Compounded Topical Pain CreamsAppendix A: Study ApproachAppendix B: Literature ReviewAppendix C: Commissioned Paper: Topical Dosage Form Development and EvaluationAppendix D: GlossaryAppendix E: 503A and 503B Distribution SupplementAppendix F: Adverse Events TableAppendix G: Potential Adverse Effects from Oral Administration of 20 Active Pharmaceutical Ingredients Commonly Used in Compounded Topical Pain CreamsAppendix H: Expanded Discussion on Special Populations to Consider in Pain ManagementAppendix I: Biographical Sketches for Committee Members, Fellow, Consultants, and Staff

DKK 500.00
1

Inclusion of Pregnant and Lactating Persons in Clinical Trials - Development Forum On Drug Discovery - Bog - National Academies Press - Plusbog.dk

Inclusion of Pregnant and Lactating Persons in Clinical Trials - Development Forum On Drug Discovery - Bog - National Academies Press - Plusbog.dk

Approximately 4 million pregnant people in the United States give birth annually, and 70 percent of these individuals take at least one prescription medication during their pregnancy. Yet, due to a number of historical, ethical, legal, scientific, and societal issues, pregnant and lactating persons are often excluded from clinical trials. As a result, pregnant and lactating persons are often taking drugs based on limited information about the benefits and risks to themselves and their developing or newborn baby. The National Academies Forum on Drug Discovery, Development, and Translation convened a workshop in June 2022 for stakeholders to examine the current state of evidence generation for drug products used by pregnant and lactating persons and discuss barriers and opportunities for including these populations in clinical trials. This publication summarizes the presentations and discussion of the workshop. Table of ContentsFront Matter1 Introduction2 Effects of Evidence Gaps in Clinical Treatment for Pregnant and Lactating Persons3 The Legal Landscape4 Lessons Learned5 Potential Practical Solutions for Including Pregnant and Lactating Persons in Clinical Trials6 Promising Innovative Approaches to Evidence Generation7 A Path Toward InclusionAppendix A: ReferencesAppendix B: Workshop AgendaAppendix C: Biographical Sketches of the Workshop Planning Committee, Speakers, and Staff

DKK 201.00
1

Medications in Single-Dose Vials - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Medications in Single-Dose Vials - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Every year, significant amounts of expensive drugs are discarded. This is due in part to the growing number of prescription drugs that are administered in variable doses (rather than fixed or flat doses) based on a patient's weight or body size. Strict regulations and guidance generally prohibit or severely restrict the acceptable time frame for sharing medication from single-dose vials among patients, and so the unused amount will typically be discarded. Due to the current system for producing, administering, and paying for drugs in the United States, significant - but indeterminate - amounts of expensive prescription drugs are discarded each year. At the request of the Centers for Medicare & Medicaid Services, Medications in Single Dose Vials: Implications of Discarded Drugs explores the federal health care costs, safety, and quality concerns associated with discarded drugs that result from the weight-based dosing of medicines contained in single-dose vials. Table of ContentsFront MatterSummary1 Introduction2 Single-Dose Vials of Weight-Based Drugs3 Scope of Discarded Drugs from Single-Dose Vials4 Efforts to Reduce Discarded Weight-Based Drugs5 Discarded Weight-Based Drugs in Single-Dose Vials6 Prescription for Reducing Discarded DrugsAppendix A: GlossaryAppendix B: Supplemental Figures and Tables from Commissioned AnalysesAppendix C: Stakeholder InputAppendix D: Biographical InformationAppendix E: Disclosure of Unavoidable Conflicts of Interest

DKK 370.00
1

Public Engagement on Facilitating Access to Antiviral Medications and Information in an Influenza Pandemic - Board On Health Sciences Policy - Bog -

Public Engagement on Facilitating Access to Antiviral Medications and Information in an Influenza Pandemic - Board On Health Sciences Policy - Bog -

Influenza pandemics overwhelm health care systems with thousands or hundreds of thousands of sick patients, as well as those worried they may be sick. In order to ensure a successful response to the patient swell caused by a pandemic, robust planning is essential to prepare for challenges public health officials may face. This includes the need to quickly distribute and dispense antiviral medications that can reduce the severity and duration of disease to large numbers of people. In response to a request from the Centers for Disease Control, the Institute of Medicine's Forum on Medical and Public Health Preparedness for Catastrophic Events held a series of workshops that explored the public's perception of how to facilitate access to antiviral medications and treatment during an influenza pandemic. To help inform potential strategies still in the development stages at the CDC, workshops were held in Fort Benton, Montana; Chattanooga, Tennessee; and Los Angeles, California during February and March 2012 to consider the usefulness of several alternative strategies of delivering antiviral medication to the public. Participants considered how the normal systems for prescribing and dispensing antiviral medications could be adjusted to ensure that the public has quick, safe, and equitable access to both potentially life-saving drugs and information about the pandemic and treatment options. This document summarizes the workshops. Table of ContentsFront MatterIntroduction and Workshop Series SummaryAppendix: Recruitment Flyer

DKK 214.00
1

Methadone Treatment for Opioid Use Disorder - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Methadone Treatment for Opioid Use Disorder - Health And Medicine Division - Bog - National Academies Press - Plusbog.dk

Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on "Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws," at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop. Table of ContentsFront Matter1 Introduction and Background2 Methadone Treatment: Personal Perspectives3 The History of Methadone and Barriers to Access for Different Populations4 Current Federal Priorities and Regulatory Flexibilities during the COVID-19 Pandemic5 Improving Access to Quality Treatment in Opioid Treatment Programs through Regulatory Innovation6 Improving Access to Quality Treatment in the Criminal Justice System and Other Institutional Settings7 Expanding Access to Methadone through Regulatory Innovation: Envisioning Approaches Outside the Opioid Treatment Program System8 Ensuring Equitable Access to Methadone by Removing Current Barriers and Providing Incentives9 Frameworks to Guide the Assessment of Legal and Regulatory Challenges10 Moving Forward: Potential Concrete Legal and Regulatory ActionsAppendix A: ReferencesAppendix B: Workshop AgendaAppendix C: Commissioned Papers

DKK 214.00
1

Health Literacy and Numeracy - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

Health Literacy and Numeracy - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

Although health literacy is commonly defined as an individual trait, it does not depend on the skills of individuals alone. Health literacy is the product of the interaction between individuals' capacities and the health literacy-related demands and complexities of the healthcare system. Specifically, the ability to understand, evaluate, and use numbers is important to making informed health care choices. Health Literacy and Numeracy is the summary of a workshop convened by The Institute of Medicine Roundtable on Health Literacy in July 2013 to discuss topics related to numeracy, including the effects of ill health on cognitive capacity, issues with communication of health information to the public, and communicating numeric information for decision making. This report includes a paper commissioned by the Roundtable, "Numeracy and the Affordable Care Act: Opportunities and Challenges," that discusses research findings about people's numeracy skill levels; the kinds of numeracy skills that are needed to select a health plan, choose treatments, and understand medication instructions; and how providers should communicate with those with low numeracy skills. The paper was featured in the workshop and served as the basis of discussion. Table of ContentsFront Matter1 Introduction2 Overview of Numeracy3 Numeracy Demands, Assumptions, and Challenges for Consumers4 Numeracy Demands, Assumptions, and Challenges for Communicators5 Strategies for Effective CommunicationAppendix A: Numeracy and the Affordable Care Act: Opportunities and ChallengesAppendix B: Meeting AgendaAppendix C: Speaker Biosketches

DKK 279.00
1

How Can Health Care Organizations Become More Health Literate? - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

How Can Health Care Organizations Become More Health Literate? - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

Approximately 80 million adults in the United States have low health literacy - an individual's ability to obtain, process, and understand basic health information. Low health literacy creates difficulties in communicating with clinicians, poses barriers in managing chronic illness, lessens the likelihood of receiving preventive care, heightens the possibility of experiencing serious medication errors, increased risk of hospitalization, and results in poorer quality of life. It is important for health care organizations to develop strategies that can improve their health literacy, yet organizations often find it difficult to determine exactly what it means to be health literate. How Can Health Care Organizations Become More Health Literate?: Workshop defines a health literate health care organization as "an organization that makes it easier for people to navigate, understand, and use information and services to take care of their health." In November 2011, the IOM Roundtable on Health Literacy held a workshop to discuss the growing recognition that health literacy depends not only on individual skills and abilities but also on the demands and complexities of the health care system. How Can Health Care Organizations Become More Health Literate?: Workshop summarizes the workshop. Table of ContentsFront Matter1 Introduction2 Attributes of a Health Literate Health Care Organization3 Reaction Panel 14 Reaction Panel 25 Reaction Panel 36 Reaction Panel 47 Reflections on Lessons LearnedAppendix A: The Other Side of the Coin: Attributes of a Health Literate Health Care OrganizationAppendix B: AgendaAppendix C: Speaker Biographical Sketches

DKK 260.00
1

Building the Case for Health Literacy - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

Building the Case for Health Literacy - Roundtable On Health Literacy - Bog - National Academies Press - Plusbog.dk

The field of health literacy has evolved from one focused on individuals to one that recognizes that health literacy is multidimensional. While communicating in a health literate manner is important for everyone, it is particularly important when communicating with those with limited health literacy who also experience more serious medication errors, higher rates of hospitalization and use of the emergency room, poor health outcomes, and increased mortality. Over the past decade, research has shown that health literacy interventions can significantly impact various areas including health care costs, outcomes, and health disparities. To understand the extent to which health literacy has been shown to be effective at contributing to the Quadruple Aim of improving the health of communities, providing better care, providing affordable care, and improving the experience of the health care team, the National Academies of Sciences, Engineering, and Medicine convened a public workshop on building the case for health literacy. This publication summarizes the presentations and discussions from the workshop, and highlights important lessons about the role of health literacy in meeting the Quadruple Aim, case studies of organizations that have adopted health literacy, and discussions among the different stakeholders involved in making the case for health literacy. Table of ContentsFront Matter1 Introduction2 The Patient Perspective on the Need for Health Literacy3 Improving Health and the Bottom Line: The Case for Health Literacy4 Why Health Literacy?5 Adopting Health Literacy in an Organization6 Where Do We Go from Here?7 Reflections on the DayReferencesAppendix A: Workshop AgendaAppendix B: Biographical Sketches of Workshop Moderators, Speakers, and PanelistsAppendix C: Improving Health and the Bottom Line: The Case for Health Literacy

DKK 396.00
1

Exploring the State of the Science of Solid Organ Transplantation and Disability - Health And Medicine Division - Bog - National Academies Press -

Exploring the State of the Science of Solid Organ Transplantation and Disability - Health And Medicine Division - Bog - National Academies Press -

Transplantation of a solid organ, such as a kidney, heart, or liver, is a lifesaving procedure and is sometimes the only viable treatment for patients experiencing end-stage organ failure as a result of illness or injury. A growing prevalence of solid organ diseases in the United States is contributing to more people needing a transplant and longer wait times on the national transplant waiting list. While transplantation can lengthen a person's life, the road to recovery is difficult and complex. Transplant recipients commonly experience considerable impairments related to health factors, medication side effects, organ rejection, or other setbacks that can cause functional limitations. A spectrum of services and supports can be beneficial to patient functioning and quality of life, but patient access is variable due to individual, system, and social factors. To gain an understanding of current scientific findings in the field of solid organ transplantation, the U.S. Social Security Administration asked the National Academies of Sciences, Engineering, and Medicine's Board on Health Care Services to organize a virtual public workshop to examine disability associated with organ transplantation. The workshop, held March 22-23, 2021, focused on kidney, heart, liver, and lung transplantation, and to a lesser extent intestine transplantation. Subject-matter experts presented on clinical aspects of post-transplantation recovery and described the implications for physical, cognitive, and psychosocial functioning in adults and children. This publication summarizes the presentations and panel discussions from the workshop. Table of ContentsFront Matter1 Introduction2 Solid Organ Transplantation in the United States and the Experiences of Organ Recipients and Their Caregivers3 Organ Transplantation and Disability in Adults4 Organ Transplantation and Disability in Children and Adolescents5 Treatments, Technologies, and Interventions Affecting Function After Transplantation6 Future Outlook for Organ Transplantation and DisabilityReferencesAppendix A: Statement of TaskAppendix B: Workshop AgendaAppendix C: Biographical Sketches of Workshop Planning Committee Members and Speakers

DKK 292.00
1

Indicators for Waterborne Pathogens - Board On Life Sciences - Bog - National Academies Press - Plusbog.dk

Indicators for Waterborne Pathogens - Board On Life Sciences - Bog - National Academies Press - Plusbog.dk

Recent and forecasted advances in microbiology, molecular biology, and analytical chemistry have made it timely to reassess the current paradigm of relying predominantly or exclusively on traditional bacterial indicators for all types of waterborne pathogens. Nonetheless, indicator approaches will still be required for the foreseeable future because it is not practical or feasible to monitor for the complete spectrum of microorganisms that may occur in water, and many known pathogens are difficult to detect directly and reliably in water samples. This comprehensive report recommends the development and use of a "tool box" approach by the U.S Environmental Protection Agency and others for assessing microbial water quality in which available indicator organisms (and/or pathogens in some cases) and detection method(s) are matched to the requirements of a particular application. The report further recommends the use of a phased, three-level monitoring framework to support the selection of indicators and indicator approaches. Table of ContentsFront MatterExecutive Summary1 Introduction and Historical Background2 Health Effects Assessment3 Ecology and Evolution of Waterborne Pathogens and Indicator Organisms4 Attributes and Application of Indicators5 New Biological Measurement Opportunities6 A Phased Approach to Monitoring Microbial Water QualityAppendix A: Emerging and Reemerging Waterborne PathogensAppendix B: Review of Previous ReportsAppendix C: Detection TechnologiesAppendix D: National Research Council Board Membership and StaffAppendix E: Committee Biographical Information

DKK 448.00
1

Health IT and Patient Safety - Institute Of Medicine - Bog - National Academies Press - Plusbog.dk

Health IT and Patient Safety - Institute Of Medicine - Bog - National Academies Press - Plusbog.dk

IOM's 1999 landmark study To Err is Human estimated that between 44,000 and 98,000 lives are lost every year due to medical errors. This call to action has led to a number of efforts to reduce errors and provide safe and effective health care. Information technology (IT) has been identified as a way to enhance the safety and effectiveness of care. In an effort to catalyze its implementation, the U.S. government has invested billions of dollars toward the development and meaningful use of effective health IT. Designed and properly applied, health IT can be a positive transformative force for delivering safe health care, particularly with computerized prescribing and medication safety. However, if it is designed and applied inappropriately, health IT can add an additional layer of complexity to the already complex delivery of health care. Poorly designed IT can introduce risks that may lead to unsafe conditions, serious injury, or even death. Poor human-computer interactions could result in wrong dosing decisions and wrong diagnoses. Safe implementation of health IT is a complex, dynamic process that requires a shared responsibility between vendors and health care organizations. Health IT and Patient Safety makes recommendations for developing a framework for patient safety and health IT. This book focuses on finding ways to mitigate the risks of health IT-assisted care and identifies areas of concern so that the nation is in a better position to realize the potential benefits of health IT. Health IT and Patient Safety is both comprehensive and specific in terms of recommended options and opportunities for public and private interventions that may improve the safety of care that incorporates the use of health IT. This book will be of interest to the health IT industry, the federal government, healthcare providers and other users of health IT, and patient advocacy groups. Table of ContentsFront MatterSummary1 Introduction2 Evaluating the Current State of Patient Safety and Health IT3 Examination of the Current State of the Art in System Safety and Its Relationship to the Safety of Health ITAssisted Care4 Opportunities to Build a Safer System for Health IT5 Patients' and Families' Use of Health IT: Concerns About Safety6 A Shared Responsibility for Improving Health IT Safety7 Future Research for Care TransformationAppendix A: GlossaryAppendix B: Literature Review MethodsAppendix C: Abstract of "Roadmap for Provision of Safer Healthcare Information Systems: Preventing e-Iatrogenesis"Appendix D: Abstract of "The Impact of Regulation on Innovation in the United States: A Cross-Industry Literature Review"Appendix E: Dissenting Statement: Health IT Is a Class III Medical DeviceAppendix F: Committee Member and Staff Biographies

DKK 312.00
1

An Assessment of ARPA-E - Committee On Evaluation Of The Advanced Research Projects Agency Energy - Bog - National Academies Press - Plusbog.dk

An Assessment of ARPA-E - Committee On Evaluation Of The Advanced Research Projects Agency Energy - Bog - National Academies Press - Plusbog.dk

In 2005, the National Research Council report Rising Above the Gathering Storm recommended a new way for the federal government to spur technological breakthroughs in the energy sector. It recommended the creation of a new agency, the Advanced Research Projects Agency-Energy, or ARPA-E, as an adaptation of the Defense Advanced Research Projects Agency (DARPA) model—widely considered a successful experiment that has funded out-of-the-box, transformative research and engineering that made possible the Internet, GPS, and stealth aircraft. This new agency was envisioned as a means of tackling the nation's energy challenges in a way that could translate basic research into technological breakthroughs while also addressing economic, environmental, and security issues. Congress authorized ARPA-E in the 2007 America COMPETES Act and requested an early assessment following 6 years of operation to examine the agency's progress toward achieving its statutory mission and goals. This report documents the results of that assessment. It includes both an operational assessment of the agency's funding programs and a technical assessment of its awards, to the extent possible. Table of ContentsFront MatterSummary1 Introduction2 Overview of ARPA-E3 ARPA-E's Internal Operations: Culture, People, and Processes4 Technical AssessmentReferencesAppendix A: Committee Member BiographiesAppendix B: Disclosure of Conflict of InterestAppendix C: Methods Used to Assess ARPA-EAppendix D: Case Studies Used to Assess ARPA-E's Operations and Potential to Achieve Energy ImpactsAppendix E: Glossary of Abbreviations and AcronymsAppendix F: Request for Data from ARPA-E, Input from Other Offices at the Department of Energy, and Agendas for Committee's Public Information Gathering SessionsAppendix G: Consultants' Reports of Data Analysis

DKK 396.00
1

To Err Is Human - Committee On Quality Of Health Care In America - Bog - National Academies Press - Plusbog.dk

To Err Is Human - Committee On Quality Of Health Care In America - Bog - National Academies Press - Plusbog.dk

Experts estimate that as many as 98,000 people die in any given year from medical errors that occur in hospitals. That's more than die from motor vehicle accidents, breast cancer, or AIDS—three causes that receive far more public attention. Indeed, more people die annually from medication errors than from workplace injuries. Add the financial cost to the human tragedy, and medical error easily rises to the top ranks of urgent, widespread public problems. To Err Is Human breaks the silence that has surrounded medical errors and their consequence—but not by pointing fingers at caring health care professionals who make honest mistakes. After all, to err is human. Instead, this book sets forth a national agenda—with state and local implications—for reducing medical errors and improving patient safety through the design of a safer health system. This volume reveals the often startling statistics of medical error and the disparity between the incidence of error and public perception of it, given many patients' expectations that the medical profession always performs perfectly. A careful examination is made of how the surrounding forces of legislation, regulation, and market activity influence the quality of care provided by health care organizations and then looks at their handling of medical mistakes. Using a detailed case study, the book reviews the current understanding of why these mistakes happen. A key theme is that legitimate liability concerns discourage reporting of errors—which begs the question, "How can we learn from our mistakes?"Balancing regulatory versus market-based initiatives and public versus private efforts, the Institute of Medicine presents wide-ranging recommendations for improving patient safety, in the areas of leadership, improved data collection and analysis, and development of effective systems at the level of direct patient care. To Err Is Human asserts that the problem is not bad people in health care—it is that good people are working in bad systems that need to be made safer. Comprehensive and straightforward, this book offers a clear prescription for raising the level of patient safety in American health care. It also explains how patients themselves can influence the quality of care that they receive once they check into the hospital. This book will be vitally important to federal, state, and local health policy makers and regulators, health professional licensing officials, hospital administrators, medical educators and students, health caregivers, health journalists, patient advocates—as well as patients themselves. First in a series of publications from the Quality of Health Care in America, a project initiated by the Institute of MedicineTable of ContentsFront MatterExecutive Summary1 A Comprehensive Approach to Improving Patient Safety2 Errors in Health Care: A Leading Cause of Death and Injury3 Why Do Errors Happen?4 Building Leadership and Knowledge for Patient Safety5 Error Reporting Systems6 Protecting Voluntary Reporting Systems from Legal Discovery7 Setting Performance Standards and Expectations for Patient Safety8 Creating Safety Systems in Health Care OrganizationsA Background and MethodologyB Glossary and AcronymsC Literature SummaryD Characteristics of State Adverse Event Reporting SystemsE Safety Activities in Health Care OrganizationsIndex

DKK 439.00
1